LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Design Therapeutics Inc

Uždarymo kaina

6.25 5.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.88

Max

6.25

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-19M

Pelno marža

-2,321.599

Darbuotojai

57

EBITDA

-1.3M

-22M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-14.53% downside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

109M

334M

Ankstesnė atidarymo kaina

0.85

Ankstesnė uždarymo kaina

6.25

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-17 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025-09-17 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025-09-17 21:59; UTC

Uždarbis

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025-09-17 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-09-17 23:39; UTC

Rinkos pokalbiai

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025-09-17 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025-09-17 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025-09-17 21:00; UTC

Uždarbis

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025-09-17 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025-09-17 19:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-09-17 18:43; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025-09-17 18:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025-09-17 18:20; UTC

Rinkos pokalbiai

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025-09-17 18:14; UTC

Rinkos pokalbiai

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025-09-17 17:59; UTC

Rinkos pokalbiai

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025-09-17 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025-09-17 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025-09-17 16:51; UTC

Uždarbis

Correct: Exor 1H Net Loss -EUR624M

2025-09-17 16:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 16:34; UTC

Rinkos pokalbiai

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025-09-17 16:25; UTC

Uždarbis

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025-09-17 16:23; UTC

Uždarbis

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

-14.53% į apačią

12 mėnesių prognozė

Vidutinis 5 USD  -14.53%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat